Toll-Like Receptor Agonist Pipeline and Clinical Trial Analysis | 60+ Companies and 60+ Drugs

DelveInsight's, "Toll Like Receptor Agonist Pipeline Insight, 2023," report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Toll- Like Receptor Agonist pipeline landscape. It covers the Toll Like Receptor Agonist pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Toll Like Receptor Agonist pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Toll Like Receptor Agonist Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Toll Like Receptor Agonist clinical trial studies, NDA approvals (if any), and product development activities comprising the technology, Toll- Like Receptor Agonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Toll Like Receptor Agonist Pipeline Report
• Over 60+ toll-like receptor agonist pipeline therapies are in various stages of development, and their anticipated acceptance in the toll-like receptor agonist market would significantly increase market revenue.
• Leading toll-like receptor agonist companies include InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and others.
• Promising toll-like receptor agonist pipeline therapies in various stages of development include P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others.
• The Toll Like Receptor Agonist Companies and academics are working to assess challenges and seek opportunities that could influence Toll- Like Receptor Agonist R&D. The Toll Like Receptor Agonist pipeline therapies under development are focused on novel approaches to treat/improve Toll- Like Receptor Agonist.

Explore more information of the latest breakthroughs in the Toll Like Receptor Agonist treatment landscape of the report, visit Toll Like Receptor Agonist Pipeline Outlook @ https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Toll-Like Receptor Agonist Treatment Landscape

• In February 2022, Primmune Therapeutics presented interim data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI). Oral administration of PRTX007 in this first-in-human study of healthy volunteers exhibited a favorable safety profile, rapid absorption and conversion to TLR7 agonist PRX034, and activation of the innate immune system without causing inflammation.

• Pattern's lead product, P2PAR-100, is an immunotherapeutic that activates innate immune cells to kill cancer cells and safely activates an efficacious innate and adaptive immune response.

Toll Like Receptor Agonist Overview

Toll-like receptors (TLRs) are a family of pattern recognition receptors and part of the first line of defense against invading microbes. TLR1, -2, -4, -5, -6, and -10 are expressed on the cell surface, whereas TLR3, -7, -8, and -9 are situated on endosomal membranes within the cell [5, 9, 10]. TLR1 and TLR2 can heterodimerize to recognize a variety of bacterial lipid structures and cell wall components, such as triacylated lipoproteins, lipoteichoic acid, and β-glucans. Engaging TLRs through their specific ligands leads to activation of the innate immune system and secondarily priming of the adaptive immune system. Because of these unique properties, TLR agonists have been investigated as immunotherapy in cancer treatment for many years, but in recent years there has also been growing interest in the use of TLR agonists in the context of human immunodeficiency virus type 1 (HIV-1) cure research.

Request a sample and discover the recent advances in Toll Like Receptor Agonist Pipeline Therapies, visit Toll Like Receptor Agonist Treatment Landscape @ https://www.delveinsight.com/sample-request/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Toll- Like Receptor Agonist Emerging Drugs

Cobitolimod: InDex Pharmaceuticals
Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis. Cobitolimod met the primary endpoint in the Phase IIb study CONDUCT and demonstrated an outstanding combination of efficacy and safety. In March 2021, InDex Pharmaceuticals announced that the company has entered an agreement for services with global clinical research organization (CRO) Parexel Biotech for the Phase III study CONCLUDE. The study will evaluate the efficacy and safety of the drug candidate cobitolimod for the treatment of moderate to severe left-sided ulcerative colitis.

Tilsotolimod: Idera Pharmaceuticals
Tilsotolimod is an investigational, synthetic Toll-like receptor 9 agonist. Intratumoral injection of tilsotolimod has been shown to promote both innate (Type-I IFN, antigen presentation) and adaptive (T cells) immune activation. Tilsotolimod has received both Fast Track designation and Orphan Drug designation from the FDA and is being evaluated in multiple tumor types and in combination with multiple checkpoint inhibitors. In March 2021, Idera Pharmaceuticals announced that ILLUMINATE-301, the Company's pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR).

Toll- Like Receptor Agonist Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Toll- Like Receptor Agonist. The companies which have their Toll- Like Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

Toll-Like Receptor Agonist Pipeline Therapies and Key Companies
• Tilsotolimod: Idera Pharmaceuticals
• Cobitolimod: InDex Pharmaceuticals
• E5564: Eisai Co Ltd
• BDB001: Seven and Eight Biopharmaceuticals
• PrEP-001: PrEP Biopharm
• BO112: Highlight Therapeutics
• BNT411: BioNTech
• NKTR-262: Nektar therapeutics
• TransCon TLR 7/8 agonist: Ascendis Pharma

Get to know more information about the Toll-Like Receptor Agonist Emerging Drugs and Companies of the report @ https://www.delveinsight.com/report-store/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

DelveInsight's report covers around 60+ products under different phases of clinical development like-
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Toll-Like Receptor Agonist Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Toll-Like Receptor Agonist Route of Administration

Toll-Like Receptor Agonist Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Toll-Like Receptor Agonist. The companies which have their Toll-Like Receptor Agonist drug candidates in the most advanced stage, i.e. Phase III include, InDex Pharmaceuticals.

Scope of the Toll-Like Receptor Agonist Pipeline Insight Report

• Coverage- Global
• Toll-Like Receptor Agonist Companies- InDex Pharmaceuticals, Mologen, Exicure, Birdie Biopharmaceuticals, Seven and Eight Biopharmaceuticals, Primmune Therapeutics, Pattern Pharma, Silverback Therapeutics, Hoffman-La-Roche, Ascendis Pharma, Nektar therapeutics, BioNTech, Highlight Therapeutics, PrEP Biopharm, TriSalus Life Sciences, Gilead Sciences, Tallac Therapeutics, Inc., ALX Oncology Holdings Inc., Checkmate Pharmaceuticals, AIM ImmunoTech, Scopus BioPharma, BrightPath Biotherapeutics, NapaJen Pharma, Ena Respiratory, Revelation Biosciences, Immune Design, Protara Therapeutics, Galderma, Bolt Biotherapeutics, Jiangsu Hengrui Medicine Co., Novartis, Elicio Therapeutics, Statera BioPharma, and others.
• Toll-Like Receptor Agonist Pipeline Therapies- P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others.
• Toll-Like Receptor Agonist Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration

For further information, refer to the detailed Toll-Like Receptor Agonist pipeline report, visit Toll-Like Receptor Agonist Emerging Drugs & Companies @ https://www.delveinsight.com/report-store/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Toll- Like Receptor Agonist Executive Summary
3. Toll- Like Receptor Agonist: Overview
4. Toll- Like Receptor Agonist Pipeline Therapeutics
5. Toll- Like Receptor Agonist Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Cobitolimod: InDex Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Cavrotolimod: Exicure
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. BDB-018: Seven and Eight Biopharmaceuticals
14. Drug profiles in the detailed report…..
15. Preclinical stage products
16. BDB-030: Seven and Eight Biopharmaceuticals
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Toll- Like Receptor Agonist Key Companies
20. Toll- Like Receptor Agonist Key Products
21. Toll- Like Receptor Agonist- Unmet Needs
22. Toll- Like Receptor Agonist- Market Drivers and Barriers
23. Toll- Like Receptor Agonist- Future Perspectives and Conclusion
24. Toll- Like Receptor Agonist Analyst Views
25. Toll- Like Receptor Agonist Key Companies
26. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Toll- Like Receptor Agonist drugs?
• How many Toll- Like Receptor Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Toll- Like Receptor Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Toll- Like Receptor Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Toll- Like Receptor Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Dive deep into rich insights for drugs for Toll- Like Receptor Agonist treatment, visit Toll- Like Receptor Agonist Market Drivers and Barriers @ https://www.delveinsight.com/report-store/toll-like-receptor-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.